Talon Marqibo’s Fate May Hang On Adjudication Of Trial Subjects
This article was originally published in The Pink Sheet Daily
Executive Summary
With Talon offering a single Phase II trial to support its NDA for Marqibo (vincristine sulfate liposomal injection) for relapsed Philadelphia chromosome negative acute lymphoblastic leukemia, everything may hinge on the disagreement between the sponsor and FDA over whether eight patients or 13 out of 65 experienced some type of complete response.
You may also be interested in...
Talon Marqibo’s Confirmatory Trial Plan May Need To Be Reworked
FDA advisory committee members express concern about the toxicity of Marqibo in the elderly patients expected to enroll in the Phase III confirmatory study for advanced acute lymphoblastic leukemia.
Talon’s Marqibo Gets Lukewarm Endorsement From ODAC
A split Oncologic Drugs Advisory Committee vote moves Talon Therapeutics’ Marqibo (vincristine sulfate liposomal injection) for relapsed Philadelphia chromosome negative acute lymphoblastic leukemia one step closer to accelerated approval.
Talon May Soon Have First Marqibo Approval In Its Grasp
Biotech formerly known as Hana Biosciences submits NDA for the nano-encapsulated vincristine for use as salvage in adults with Ph- ALL.